AzTrials
AzTrials

Coronary Artery DiseaseMAGICAL SVNCT06271590

MagicTouch™Sirolimus-Coated Balloon for Treatment of Coronary Artery Lesions in Small Vessels

A study testing Sirolimus Drug Coated Balloon and Drug eluting stents (DES) in people with Coronary Artery Disease and Native Coronary Artery Stenosis, run by Concept Medical Inc. at 24 sites in United States.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

This is a multicenter, randomized, single-blind pivotal study to evaluate the safety and efficacy of the MagicTouchTM Drug coated balloon in treatment of small vessels in patients with coronary artery disease. Read more about this study

Who is it for?
Ages 18 to 80 years
What is being tested?
Sirolimus Drug Coated Balloon and Drug eluting stents (DES)
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
1,605 participants
Where
24 sitesUnited States
Study dates
20 May 2025to Nov 2031
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 80 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Clinical Inclusion Criteria:

  1. Adult patient with an indication for PCI due to stable angina, NSTEACS, post-infarction angina or silent ischemia (in absence of symptoms a visually estimated target lesion diameter stenosis of ≥70%, a positive non-invasive stress test, FFR ≤0.80, or non-hyperemic pressure ratio [NHPR] ≤0.89 must be present)
  2. Subject is ≥18 and <80 years old
  3. Subject is willing to comply with all protocol-required follow-up evaluations and provides written informed consent Angiographic Inclusion Criteria:
  4. Target reference vessel diameter (visual estimation) ≤2.75 mm
  5. Successful lesion preparation (residual stenosis <30%), without flow-limiting complications (no or slow flow, dissection etc.)
  6. Target lesion(s) in a native coronary artery
  7. Up to two small vessel target lesions in two different vessels
  8. Target lesion length (visual estimation): ≥6.0 and ≤34.0 mm and can be covered by a single 40 mm balloon
  9. Target lesion diameter stenosis (visual estimation) >30% and <100% with Thrombolysis in Myocardial Infarction (TIMI) flow grade ≥2

Clinical Exclusion Criteria:

  1. Planned (staged) intervention in the target vessel
  2. ST-segment-elevation MI within 48 hours prior to index procedure
  3. Subjects with acute cardiac decompensation or cardiogenic shock
  4. Subject with a life expectancy of less than 24 months
  5. Impaired renal function (glomerular filtration rate [GFR] <30 mL/min)
  6. Documented left ventricular ejection fraction (LVEF) ≤30%
  7. Known allergies to acetylsalicylic acid, clopidogrel, prasugrel, ticagrelor, heparin, contrast medium, sirolimus or similar drugs (i.e., ABT-578 [Zotarolimus], biolimus, tacrolimus)
  8. Relative or absolute contraindication to dual antiplatelet therapy (DAPT) for at least 1 month (e.g., planned surgeries that cannot be delayed)
  9. Subject has an indication for chronic oral anticoagulation treatment and a contraindication for concomitant treatment with a P2Y12 inhibitor
  10. If femoral access is planned, significant peripheral arterial disease which precludes safe insertion of a 6F sheath
  11. Hemoglobin <9 g/dL
  12. Platelet count <100,000 cells/mm3 or >700,000 cells/mm3
  13. White blood cell count <3,000 cells/mm3
  14. Active infection undergoing treatment
  15. Clinically significant liver disease
  16. Cerebrovascular accident (CVA) within 3 months or has any permanent neurological defect as a result of CVA
  17. Subject is receiving oral or intravenous immunosuppressive therapy (e.g., inhaledsteroids are not excluded) or has known life-limiting immunosuppressive or autoimmune disease (e.g., human immunodeficiency virus, systemic lupus erythematosus, but not including diabetes mellitus)
  18. Subject is unlikely to comply with the follow up requirements, per investigator's assessment
  19. Subject currently enrolled in other investigational device or drug trial in which primary endpoint has not been reached
  20. Pregnant and/or breast-feeding females or females who intend to become pregnant during the time of the study Angiographic Exclusion Criteria: All exclusion criteria apply to the target lesion(s) or target vessel(s)
  21. Re-stenotic lesion(s), whether due to percutaneous old balloon angioplasty (POBA) or prior stenting
  22. True bifurcation lesion (lesion involves both main and side branch>2.5 mm) with planned treatment of both branches per investigator assessment
  23. Angiographic evidence of thrombus in the target vessel
  24. Myocardial bridging
  25. Target lesion is heavily calcified
  26. Diffuse distal disease to target lesion with impaired runoff, TIMI flow <2
  27. Non-target lesion in the target vessel requiring PCI

Note: Non-target vessel PCI is allowed at the time of index procedure if performed prior to study intervention and if successful and uncomplicated. For target lesions located in branches of the three main vessels (left anterior descending artery [LAD], left circumflex artery [LCx], right coronary artery [RCA]), the term target vessel refers to the branch and not the main vessel.

Trial locations and contacts

24 sites in 1 country. Contact the study team or a site near you to ask about taking part.

24 sites in 1 country

United States24 sites, 24 recruiting
  • Emory University Hospital /Emory School of Medice

    Atlanta, Georgia, 30322

    Mutsa Seremwe, 404-712-5622, mutsa.seremwe@emory.edu

    Not yet recruiting
  • University Hospitals, Cleveland Medical Center

    Brooklyn, New York, 11215

    Jhané Phanor, 917-679-1951, jhp4004@nyp.org

    Not yet recruiting
  • Clearwater Cardiovascular and Interventional Consultants

    Clearwater, Florida, 33756

    Jessica Cain, 727-467-9393, cainj@cccheart.com

    Recruiting
  • University Hospitals, Cleveland Medical Center

    Cleveland, Ohio, 44106

    Stacey Mazzurco, 12169785519, Stacey.Mazzurco@uhhospitals.org

    Not yet recruiting
  • Cleveland Clinic

    Cleveland, Ohio, 44195

    Claire Licina, 216-442-5574, licinac@ccf.org

    Not yet recruiting
  • Atlanta VA Medical Center

    Decatur, Georgia, 30033

    Susan Muly, 4042638204, Susan.Muly@va.gov

    Not yet recruiting
  • Dignity Health - Mercy Gilbert Medical Center

    Gilbert, Arizona, 85297

    Jennifer Zumbuhl, 480-728-9973, Jennine.Zumbuhl@commonspirit.org

    Not yet recruiting
  • University of Florida Health Sciences Center-Jacksonville

    Jacksonville, Florida, 32209

    Andrea Burlton, 904-244-5617, andrea.burton@ufhealth.org

    Not yet recruiting
  • Cedars-Sinai Medical Center

    Los Angeles, California, 90048

    Mitch Gheorghiu, 310 4236152, mitch.gheorghiu@cshs.org

    Not yet recruiting
  • North Shore University Hospital - Northwell

    Manhasset, New York, 11030

    Emma Graze, 516-562-4100, clinicalresearch@northwell.edu

    Not yet recruiting
  • Loyola University Medical Center

    Maywood, Illinois, 60153

    Tracy Bielecki Smith, 7083272761, tbielecki@luc.edu

    Not yet recruiting
  • West Virginia University Heart & Vascular Institute

    Morgantown, West Virginia, 26506

    Kimberly Quedado, 304-285-1980, Kimberly.Quedado@wvumedicine.org

    Not yet recruiting
  • Icahn School of Medicine at Mount Sinai/ Mount Sinai Hospital

    New York, New York, 10029

    Nimisha Baruah, 212-241-9687, nimisha.baruah@mountsinai.org

    Recruiting
  • Columbia University/NYP

    New York, New York, 10032

    Treena Williams, 212-342-3485, taw2112@cumc.columbia.edu

    Not yet recruiting
  • University of Oklahoma Health Science Center

    Oklahoma City, Oklahoma, 73104

    Aurora Vera, 405-308-3570, Aurora-Vera@ouhsc.edu

    Not yet recruiting
  • University of Pittsburgh Medical center (UPMC)

    Pittsburgh, Pennsylvania, 15123

    Kristin Shoemaker, 412-692-2769, shoeka@UPMC.EDU

    Not yet recruiting
  • Baylor Scott & White The Heart Hospital - Plano

    Plano, Texas, 75093

    Walter Cerqueira, 817-922-2586, walter.cerqueira@bswhealh.org

    Recruiting
  • Atlanticare Regional Medical Center

    Pomona, New Jersey, 08401

    Jacqueline White, 609-404-7654, JMWhite@atlanticare.org

    Recruiting
  • Providence St. Vincent Medical Center

    Portland, Oregon, 97225

    Bethany Wilson, 503-2167275, bethany.wilson@providence.org

    Not yet recruiting
  • NC Heart and Vascular Research, LLC

    Raleigh, North Carolina, 27607

    Rebecca Palermo, (919) 745-0750, Rebecca.palermo@unchealth.unc.edu

    Not yet recruiting
  • Tallahassee Research Institute

    Tallahassee, Florida, 32308

    Wendie Najdowski, 850-431-5024, Wendie.Najdowski@tmh.org

    Not yet recruiting
  • Tampa General Hospital / University of South Florida

    Tampa, Florida, 33606

    Gabriel Parker, (813) 810-5700, gparker4@usf.edu

    Not yet recruiting
  • Montefiore Medical Center

    The Bronx, New York, 10467

    Regina Hanstein, 646-648-6125, hanstein@montefiore.org

    Recruiting
  • North Mississippi Medical Center

    Tupelo, Mississippi, 38801

    Yvonne Ray, (662) 377-5447, YRay@nmhs.net

    Not yet recruiting

Other trials in United States

About this study

Official title: The MAGICAL SV Trial - A Prospective, Multicenter, Randomized, Two-Arm, Single-blind Non Inferiority Trial to Evaluate the Safety and Efficacy of the MagicTouch™ Sirolimus-Coated Balloon in the Treatment of Small Vessels in Patients With Coronary Artery Disease.

This is a multicenter, randomized, single-blind pivotal study to evaluate the safety and efficacy of the MagicTouchTM Drug coated balloon in treatment of small vessels in patients with coronary artery disease. The objective is to establish the safety and efficacy of the Magic TouchTM Drug coated balloon in treatment of small vessels (≤2.75 mm).

A total of 1605 subjects will be enrolled in a maximum of 50 study sites located in North America. Additional sites located in Europe and South America may also participate in the study, with non-US sites contributing a maximum of ~50% of enrollees.

Read the detailed description

Subjects with small vessel CAD (Coronary artery disease) presenting with lesions undergoing PCI (Percutaneous coronary intervention) will be randomized into two groups: treatment with the MagicTouch™ sirolimus-coated balloon or DCB (drug-coated balloon) on a 2:1 basis. Approximately 1605 subjects will be enrolled in the randomized study.

Treatment of a single lesion in a single major coronary artery or side branch will be enrolled per the inclusion and exclusion criteria. Target lesion must be located in a native coronary artery with a visually estimated diameter of<2.75 mm to length (including tandem lesions) ≤34.0 mm by visual estimation, and diameter stenosis ≥50% to <100% in symptomatic patients or ischemia by coronary physiology in patients without symptoms. The primary endpoint is TLF (target lesion failure) at 12 months after intervention.

All subjects providing informed consent will have their medical history reviewed and will undergo a physical examination, laboratory screen, and a standardized 12-lead ECG within 7 days of procedure. Women of childbearing potential will have a pregnancy test within one week prior to the procedure. SAQ-7 (Seattle Angina Questionnaire) will be collected at baseline, 30 days, 6 months, and 12 months and prior to any planned intervention.

Being tested
Sirolimus Drug Coated Balloon, Drug eluting stents (DES)
Keywords
Drug coated balloon, Sirolimus coated balloon, De Novo, Magic Touch, SCB, Concept Medical, Small Vessel, MAGICAL SV
Medical subject headings
Coronary Artery Disease, Cardiovascular Diseases

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Sirolimus Drug Coated BalloonDevice

    Also called Drug coated Balloon

    Magic TouchTM (Concept Medical) is a semi-compliant sirolimus drug coated balloon (SCB) for PCI, based on a polymer-free and nanocarrier based drug delivery technology.

  • Drug eluting stents (DES)Device

    For subjects randomized to the control group (DES), the treating physician will choose an FDA cleared DES (ZES or EES) and follow lesion preparation and stent deployment according to the Instructions per use (IFU) and institutional practices.

Study groups in NCT06271590
Study groupRoleWhat they receive
MagicTouch Sirolimus-Coated Balloon (SCB)ExperimentalMagic TouchTM is a Sirolimus Coated Balloon catheter intended to be used in coronary applications, treats the atherosclerosis of the coronary arteries by eluting the immunosuppressant agent Sirolimus without leaving behind a metallic scaffold.
Receives: Device: Sirolimus Drug Coated Balloon
Drug eluting stents (DES)Active comparatorEverolimus eluting stents (EES) or Zotarolimus eluting stents (ZES)
Receives: Device: Drug eluting stents (DES)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Target lesion failure (TLF)

    the composite of cardiovascular mortality, target-vessel myocardial infarction (TV-MI) and ischemia driven target lesion revascularization

    Measured: within 12 months

Secondary outcomes (20)
  1. Procedural success

    defined as residual diameter stenosis <30% (DS), no flow-limiting dissection and with post-procedure The thrombolysis in myocardial infarction (TIMI) 3 flow, without the need for bailout stenting

    Measured: at baseline, during the procedure

  2. Target lesion failure (TLF)

    defined as the composite of cardiovascular mortality, target-vessel myocardial infarction (TVMI) and ischemia driven target lesion revascularization

    Measured: 30 days and at 6, 12, 24, 36, 48, and 60 months

  3. Ischemia driven target vessel revascularization (ID-TVR)

    Repeat revascularization of the target lesion due to recurrent ischemia

    Measured: 30 days and at 6, 12, 24, 36, 48, and 60 months

  4. Target vessel revascularization (TVR)

    Repeat revascularization of the target vessel

    Measured: 30 days and at 6, 12, 24, 36, 48, and 60 months

  5. Any revascularization

    any repeat PCI

    Measured: 30 days and at 6, 12, 24, 36, 48, and 60 months

  6. Target vessel failure (TVF)

    defined as the composite of cardiovascular mortality,ischemia driven TVR and TVMI

    Measured: 30 days and at 6, 12, 24, 36, 48, and 60 months

  7. Q-wave myocardial infarction (MI)

    Myocardial Infarction demonstrated by new pathological Q waves on ECG

    Measured: 30 days and at 6, 12, 24, 36, 48, and 60 months

  8. Non Q-wave myocardial infarction (MI)

    Myocardial Infarction not demonstrated by new pathological Q waves on ECG

    Measured: 30 days and at 6, 12, 24, 36, 48, and 60 months

  9. Any myocardial infarction (MI)

    Measured: 30 days and at 6, 12, 24, 36, 48, and 60 months

  10. Target vessel myocardial infarction (TV MI)

    Measured: 30 days and at 6, 12, 24, 36, 48, and 60 months

  11. Spontaneous myocardial infarction (MI)

    Measured: 30 days and at 6, 12, 24, 36, 48, and 60 months

  12. Procedural myocardial infarction (MI)

    Measured: Evaluated at 48 hours

  13. Cardiovascular mortality

    Measured: 30 days and at 6, 12, 24, 36, 48, and 60 months

  14. All-cause mortality

    Measured: 30 days and at 6, 12, 24, 36, 48, and 60 months

  15. Cardiovascular mortality or myocardial infarction (MI)

    Measured: 30 days and at 6, 12, 24, 36, 48, and 60 months

  16. All-cause mortality or MI

    Measured: 30 days and at 6, 12, 24, 36, 48, and 60 months

  17. All-cause mortality, myocardial infarction (MI) or target vessel revascularization (TVR)

    Measured: 30 days and at 6, 12, 24, 36, 48, and 60 months

  18. Any probable or definite stent thrombosis

    Measured: Evaluated at 48 hours

  19. Probable stent thrombosis

    Defined as per the Academic Research Consortium (ARC) criteria

    Measured: 30 days and at 6, 12, 24, 36, 48, and 60 months

  20. Definite stent thrombosis

    Defined as per the Academic Research Consortium (ARC) criteria

    Measured: 30 days and at 6, 12, 24, 36, 48, and 60 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted22 Feb 2024
  2. Study start20 May 2025
  3. Primary completionNov 2028 (estimated)
  4. Study completionNov 2031 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
2:1 randomized trial (MagicTouchTM Sirolimus-Coated Balloon VS Drug eluting stent (ZES or EES)
Masking
Double blind
Who is masked
Participant, Outcomes assessor
Enrolment
1,605 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06271590
Sponsor's protocol ID
CM-US-R03
Acronym
MAGICAL SV
Status last verified
Sep 2025
First submitted
13 Feb 2024
Last updated
11 Sep 2025
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Sirolimus Drug Coated Balloon and Drug eluting stents (DES) in people with Coronary Artery Disease and Native Coronary Artery Stenosis, run by Concept Medical Inc. at 24 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 11 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 24 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Farhana Siddique (+919725495366, farhana@conceptmedical.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Target lesion failure (TLF) (time frame: within 12 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Sep 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in